Artisan Partners, an investment management company, released its fourth-quarter 2025 investor letter for “Artisan Mid Cap Value Fund”. A copy of the letter can be downloaded here. The Fund seeks to ...
Bio-Rad is a "picks and shovels" company in the life sciences industry, but lacks standout growth, margins, or returns, and that has been largely true for more than two decades. Recent trends in the ...
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that Roop K. Lakkaraju ...
Longleaf Partners, managed by Southeastern Asset Management, released its fourth-quarter 2025 investor letter for “Longleaf ...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based ...
With a market cap of $9.5 billion, Bio-Rad Laboratories, Inc. (BIO) operates in the healthcare and life sciences industry. The Hercules, California-based company develops and manufactures a wide range ...
Bio-Rad is back on the table as an attractive value proposition once again. The firm is well-positioned to unlock tremendous value for shareholders looking ahead, in my estimation. Profitability is a ...
While analyzing Bio-Rad Laboratories’ (BIO) most recent 10-K, my firm’s analysts noticed that its non-operating income not only overstates GAAP net income but could negatively impact the firm’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results